LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Real-Time PCR-Based Serological Diagnosis of Human Granulocytic Anaplasmosis

By LabMedica International staff writers
Posted on 26 Dec 2022
Print article
Image: Anaplasma phagocytophilum morulae (arrowed) in the cytoplasm of white blood cells (Photo courtesy of Johan S.Bakken, MD, PhD and Stephen Dumler, MD)
Image: Anaplasma phagocytophilum morulae (arrowed) in the cytoplasm of white blood cells (Photo courtesy of Johan S.Bakken, MD, PhD and Stephen Dumler, MD)

Human granulocytic anaplasmosis (HGA) is a tick-borne infection caused by the intracellular bacterium Anaplasma phagocytophilum, an emerging pathogen. HGA can manifest as a subclinical infection; however, most symptomatic persons have fever, myalgia, and headache associated with thrombocytopenia, leukopenia, and elevated transaminase levels.

Laboratory diagnosis of HGA can be established by using microscopy, serology, or nucleic acid amplification test (NAAT). Microscopy can be used to diagnose acute infections, but relies on experienced personnel to visualize intragranulocytic clusters or morulae in peripheral blood. Serology is more commonly used to diagnose HGA, relying primarily on indirect immunofluorescence assays.

Clinical Scientists at the University of Manitoba (Winnipeg, MB, Canada) and their colleagues tested two different serum specimen groups for A. phagocytophilum DNA. The first group consisted of serum samples from persons who were positive for A. phagocytophilum by using the NAAT of whole blood. The second group consisted of acute and convalescent serum samples.

The team isolated DNA from 100 μL of serum by using DNeasy 96 kits (Qiagen, Venlo, The Netherlands). The used carrier RNA (Applied Biosystems/Thermo Fisher Scientific, Waltham, MA, USA) to improve recovery of low amounts of nucleic acids and amplified the msp2 gene of A. phagocytophilum. The scientists performed amplifications on a ViiA7 system (Applied Biosystems). They also used the semiquantitative Focus Diagnostics A. phagocytophilum IFA IgG kit (DiaSorin, Saluggia, Italy), and IgG titers >1:64 indicated current or previous A. phagocytophilum infection. They defined seroconversion as a >4-fold increase in titer between acute and convalescent serum samples.

The investigators reported that of 154 paired acute and convalescent serum samples submitted for Anaplasma serology, 19 (12.3%) acute specimens and three (1.9%) convalescent specimens were PCR positive. Average Ct values were 30.3 (range 23.7–37.5) for acute samples and 34.3 (range 27.6–39.9) for convalescent samples. They did not observe seroconversion in 10 (52.6%) patients who had PCR-positive acute serum specimens.

Of the 154 paired acute and convalescent serum samples, 28 (18.2%) were serologically positive, but only 11 (7.1%) demonstrated seroconversion. Titers increased from <1:64 to 1:64 in three paired samples, 13 samples demonstrated stable or decreasing titers, and one titer doubled. PCR of acute samples detected 9/11 (81.8%) patients who displayed seroconversion. PCR was negative using acute serum samples for two patients; those patient samples had initial IFA titers >1:1024, indicating either previous infection or delayed sampling. The sensitivity of serum-based PCR was 81.8%, and specificity was 93.0% compared with seroconversion.

The authors concluded that while whole blood is the optimal specimen for anaplasmosis diagnosis, but might not be available in all cases. The PCR tested serum samples collected in Canada for Anaplasma serology and found 84.8%–95.8% sensitivity and 2.8 average cycle threshold elevation. Serum can be acceptable for detecting Anaplasma spp. when whole blood is unavailable. The study was published in the January 2023 issue of the journal Emerging Infectious Diseases.

Related Links:
University of Manitoba
Qiagen
Applied Biosystems
DiaSorin

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.